C. Horn

发表

AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon.

Z. Lu, G. Sandusky, J. Graff, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

Spyro Mousses, Michael Bittner, Galen Hostetter, 2007, Nature.

Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors.

V. Oza, P. Lyne, J. Janetka, 2008, Bioorganic & medicinal chemistry letters.

A platelet biomarker for assessing phosphoinositide 3-kinase inhibition during cancer chemotherapy

James E. Thomas, L. Green, C. Horn, 2007, Molecular Cancer Therapeutics.

Cloning, expression, purification, and characterization of the human Class Ia phosphoinositide 3-kinase isoforms.

J. A. Radding, James E. Thomas, J. Cook, 2004, Protein expression and purification.

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

Stephen Green, B. Caleb, G. Schwartz, 2008, Molecular Cancer Therapeutics.

Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors

E. Raymond, H. Riess, S. Faivre, 2015, Investigational New Drugs.

Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas.

J. Breed, V. Oza, P. Lyne, 2012, Journal of medicinal chemistry.

Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors.

Jon Read, Mei Su, J. Breed, 2012, Bioorganic & medicinal chemistry letters.

Discovery of a novel class of triazolones as checkpoint kinase inhibitors--hit to lead exploration.

J. Breed, V. Oza, P. Lyne, 2010, Bioorganic & medicinal chemistry letters.

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

B. Caleb, G. Schwartz, J. Janetka, 2008, Molecular Cancer Therapeutics.

Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors.

P. Lyne, J. Janetka, S. Ashwell, 2008, Bioorganic & medicinal chemistry letters.